Generic drug impurities draft guidance
FDA releases draft guidance entitled "ANDAs: Impurities in Drug Substances." The document, published in the Federal Register Jan. 31, is the first revision of the original 1999 guidance. The draft guidance suggests companies use stability studies, chemical development studies and routine batch analysis to test for impurities, which can be qualified in four ways...
You may also be interested in...
A revised FDA draft guidance updates recommendations on the listing and qualification of degradation products in ANDAs
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.